pancreatic cancer
Conditions
Interventions
None listed
Sponsors
Kitasato University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: patients who had been already obtained informed consent for nab-PTX+GEM combination chemotherapy before registration time; histologically proven unresectable pancreatic adenocarcinoma or adenosquamous carcinoma; age more than 75 years; an expected survival period of more than 3 months; Eastern Cooperative Oncology Group performance status 0-1; measurable lesion by RECIST.(Ver.1.1); no prior chemotherapy and radiotherapy; adequate organ function as evidenced by the following laboratory studies within 7 days prior to enrollment (leukocyte count </=12,000/mm3, neutrophil count >= 1.500/mm3, hemoglobin >= 9.0 g/dl, platelets >= 100,000/mm3, AST/ALT </= ULN x 2.5 U/L, total bilirubin </= ULN x 1.25 mg/dL, creatinine clearance>= 60 ml/min, CRP </=1.5 mg/dL, HbA1c <8.4%,); no abnormal electrocardiogram; patients with agreement of this cohort study.
Exclusion criteria
Exclusion criteria: age less than 75 years; impossible to use both iodine and gadolinium due to being allergic to contrast agent; severe mental disorders; any other cases who are regarded as inadequate for study enrollment by investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| adverse events, completion rates of two cycles chemotherapy, relative dose intensity, postponed rates of chemotherapy, reduced rates of dose, disease control rate and progression free survival | — |
Countries
Japan
Contacts
Public ContactKosuke Okuwaki
Kitasato University School of Medicine Department of Gstroenterology
Outcome results
None listed